PapersPMID:32134758
Randomized trial of intracoronary adenosine as adjunctive therapy for prevention of the no-reflow phenomenon.
- findings
- 3
- compound
- 1
- endpoints
- 3
- Study, every finding
- RCT
- Dose studied, every finding
- two intracoronary bolus doses, before and after stenting; amount not stated in the abstract
No finding here moved its endpoint.
What did not
How to read these marks →“Also, post-interventional clinical outcomes, including arrhythmia, left ventricular ejection fraction, hospitalization time, and 30 days mortality were similar between Adenosine and placebo groups.”
- Population
- Patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention; intracoronary adenosine versus intracoronary normal saline
- No detected effect on hospital length of stay
very limited
- Population
- Patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention; intracoronary adenosine versus intracoronary normal saline
- No detected effect on all-cause mortality
very limited
- Duration
- 4 weeks
- Population
- Patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention; intracoronary adenosine versus intracoronary normal saline; 30-day horizon
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention
- Participants
- 104
- Comparator
- placebo
- Duration
- not reported
- Endpoints measured
- 6